Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.
Yuru FanXuan ZhangQin ZhangLiang ZhengRenpeng ZhouCheng SunXihan WangKe SongZhusheng HeHonghui WangQian ZhangWei HuPublished in: Clinical pharmacokinetics (2024)
Clinical trials.gov, identifier: NCT05274516. Trial registration date: March 10, 2022.